Accepted Manuscript

Cellular senescence and tumor promotion: Is aging the key?

Natalia Loaiza, Marco Demaria

 PII:
 S0304-419X(16)30016-6

 DOI:
 doi: 10.1016/j.bbcan.2016.01.007

 Reference:
 BBACAN 88078

To appear in: BBA - Reviews on Cancer

Received date: Revised date: Accepted date: 23 December 2015 29 January 2016 31 January 2016



Please cite this article as: Natalia Loaiza, Marco Demaria, Cellular senescence and tumor promotion: Is aging the key?, *BBA - Reviews on Cancer* (2016), doi: 10.1016/j.bbcan.2016.01.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Cellular senescence and tumor promotion: is aging the key?

Natalia Loaiza¹, Marco Demaria^{1,2*}

¹University Medical Center Groningen (UMCG), Groningen, The Netherlands; ²European Research Institute for the Biology of Aging (ERIBA), Groningen, The Netherlands; ^{*}Correspondence to: m.demaria@umcg.nl

Abstract

The senescence response is a potent tumor suppressor mechanism characterized by an irreversible growth arrest in response to potentially oncogenic signals to prevent proliferation of damaged cells. Late in life some of the features of senescent cells seem to mediate the development of age-related pathologies, including cancer. In the present review, we present a summary of the current knowledge regarding the causes, effector pathways and cellular features of senescence. We also discuss how the senescence response, initially a tumor suppressor mechanism, turns into a tumor promoter apparently as a consequence of aging. We argue that three age-related phenomena—senescence-associated secretory phenotype (SASP) dysregulation, decline in the immune system function and genomic instability—could contribute, independently or synergistically, to deteriorate the efficacy of the senescence response in stopping cancer. As a consequence, senescent cells could be considered premalignant cells, and targeting senescent cells could be a preventive and therapeutic strategy against cancer.

Download English Version:

https://daneshyari.com/en/article/10895533

Download Persian Version:

https://daneshyari.com/article/10895533

Daneshyari.com